ClinicalTrials.gg
Active, not recruitingNCT05138133IRISUpdated Oct 28, 2026

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

A Phase 3 interventional study of Anifrolumab and Placebo in Lupus Nephritis, sponsored by AstraZeneca. Active, not recruiting at 164 sites in 24 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Enrollment
5th of 88
363 · median 51
Started
2022
with 5 others
Phase 3
20 of 96
6 open now
Primary completion
2027-02
later than 20 of 45 live
Registered
45th of 96
by date

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 5th largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2022, is one of 20 in phase 3, reaches primary completion later than 20 of the 45 other live ones, and was the 45th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis

Read the detailed description

This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study with OLE is to evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V). The total study duration may be up to approximately 142 weeks, including screening and follow-up. Double-blind period will be 76 weeks. Participants who complete double-blind treatment period may enter open-label extension to receive anifrolumab for up 52 weeks. Approximately 360 of the enrolled participants will be randomly assigned to study intervention (anifrolumab or placebo) at a ratio of 1:1 during double-blind treatment period.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • Lupus Nephritis, anifrolumab, Systemic Lupus Erythematosus, intravenous
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Active proliferative LN Class III or IV either with or without the presence of Class V according to the 2003 ISN/RPS classification
  2. Renal obtained within 6 months prior to signing the ICF or during Screening Period.
  3. Urine protein to creatinine ratio > 1 mg/mg (113.17 mg/mmol)
  4. ≥ 35 mL/min/1.73 m2 (as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula).
  5. Fulfills updated 2019 EULAR/ACR SLE classification criteria.
  6. No signs of symptoms of active TB prior to or during screening or no treatment for latent TB

Exclusion criteria

Exclusion Criteria:

  1. A diagnosis of pure Class V LN based on the renal obtained within 6 months prior to signing the ICF or during Screening.
  2. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection, or a positive result for confirmed by the central lab at Screening - an HIV test must be performed during Screening, and the result should be available prior to Week 0 (Day 1).
  3. Evidence of or active .
  4. Any history of cancer except sucessfully cured skin squamos or basal skin carcinoma and cervical cancer in situ.
  5. Receipt of the following for the current LN flare (ie, since the qualifying renal biopsy): IV cyclophosphamide > 2 pulses of high-dose (≥ 0.5 g/m2) or > 4 doses of low dose (500 mg every 2 weeks) or Average MMF > 2.5 g/day (or > 1800 mg/day of enteric coated mycophenolate sodium) for more than 8 weeks or Tacrolimus > 4 mg/day for more than 8 weeks; Cyclosporine for more than 8 weeks or during last 8 weeks prior to signing the ICF; Voclosporin for more than 8 weeks or during last 8 weeks prior to signing the ICF; Belimumab for more than 12 weeks or during last 12 weeks prior the ICF.
  6. Previous receipt of >◦2 investigation treatments (other than anifrolumab) for LN or SLE since time of diagnosis and through the ICF.
  7. Known intolerance to ≤ 1.0 g/day of MMF.
  8. Any history of severe COVID-19 infection.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    Solution for intravenous infusion

    Drug: Anifrolumab

  • Placebo comparator
    Placebo

    Solution for intravenous infusion

    Drug: Placebo

Interventions

  • Anifrolumab intravenous infusion (IV)

    Also known as: Medi-546

  • DrugPlacebo

    Placebo intravenous infusion (IV)

06

What researchers measure

Primary outcomes

  1. Difference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo group

    CRR is defined as: * UPCR ≤ 0.5 mg/mg * eGFR ≥ 60 mL/min/1.73 m2 or no decrease from baseline of ≥ 20%

    Time frame: Week 52

Secondary outcomes

  1. Difference in proportion of participants achieving sustained OCS reduction in anifrolumab group compared with placebo group

    Sustained OCS reduction

    Time frame: from Week 24 through Week 52

  2. HR of achieving sustained CRR in anifrolumab compared with placebo group

    The endpoint for deriving the summary measure is time to sustained CRR, defined as time to achieving CRR that is sustained from that time point through week 52

    Time frame: baseline through Week 52

  3. Difference in the mean standardized AUC for UPCR between anifrolumab and placebo participants

    Proteinuria as measured by the cumulative UPCR

    Time frame: baseline through Week 52

  4. Difference in proportion of participants with CRR in anifrolumab group compared with placebo group

    CRR at week 24

    Time frame: Week 24

  5. HR to summarize the difference in the risk of hazard of renal-related event or death at any given time between anifrolumab and placebo participants

    Onset of renal-related event or death through Week 52

    Time frame: Through Week 52

  6. HR to summarize the difference in the risk of hazard of renal-related event or death at any given time between anifrolumab and placebo participants

    Onset of renal-related event or death through Week 76

    Time frame: Through Week 76

  7. Difference between anifrolumab and placebo in proportions of participants who achieve aCRR

    aCRR (alternative complete renal response) defined as; * UPCR ≤ 0.5 mg/mg * eGFR ≥ 90 mL/min/1.73 m2 or no decrease from baseline of ≥ 10%

    Time frame: Week 52

  8. Difference between anifrolumab and placebo in proportions of participants who achieve CRR with sustained OCS reduction

    CRR at Week 52 with Sustained OCS Reduction

    Time frame: Week 52

  9. HR of achieving sustained CRR in anifrolumab compared to placebo group

    Time to sustained CRR through the time frame period

    Time frame: Through week 76

  10. HR of achieving 50% reduction in UPCR in anifrolumab compared to placebo group

    The endpoint for deriving the summary measure is time from the first dose of study intervention to achieving 50% reduction in UPCR

    Time frame: Through Week 52

  11. Difference in mean UPCR between the anifrolumab and placebo group

    Proteinuria as measured by UPCR

    Time frame: Week 52

  12. Difference in proportion of participants achieving PRR (Partial Renal Response) in anifrolumab group compared with placebo group

    PRR defined as: UPCR \<1.0 mg/mg (for participants with baseline UPCR ≤3 mg/mg) or \>50% improvement and ≤3 mg/mg (for participants with baseline UPCR \>3 mg/mg) eGFR ≥ 60 mL/min/1.73 m2 or no confirmed decrease of ≥20% from baseline

    Time frame: Week 52

  13. Difference in change from baseline in extra-renal SLEDAI-2K total score

    The extra-renal SLEDAI-2K score is obtained by summing the SLEDAI-2K items without including the items within the renal system organ

    Time frame: Through Week 76

  14. Difference in mean change from baseline in domains and component scores of Short Form-36 Version 2 (SF-36v2) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-fatigue) total score

    To evaluate patient-reported HRQOL and health status

    Time frame: Week 52

07

Study locations

164 sites
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    La Palma, California 90623, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Atlanta, Georgia 30308, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    Manhasset, New York 11030, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Middleburg Heights, Ohio 44130, United States
  • Research Site
    Colleyville, Texas 76034, United States
  • Research Site
    Edinburg, Texas 78539, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    CABA, C1425EOE, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1015ABO, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Rosario, S2000PBJ, Argentina
  • Research Site
    San Juan, 5400, Argentina
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Belo Horizonte, 30130 100, Brazil
  • Research Site
    Campinas, 13087-567, Brazil
  • Research Site
    Cuiabá, 78020-500, Brazil
  • Research Site
    Maringá, 87060-040, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Recife, 50740-465, Brazil
  • Research Site
    Salvador, 40150-150, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 04014-002, Brazil
  • Research Site
    São Paulo, 04036-002, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Guangzhou, 510530, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Jining, 272011, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shengyang, 110004, China
  • Research Site
    Shenzhen, 518036, China
  • Research Site
    Shijiazhuang, 050001, China
  • Research Site
    Tianjin, 300201, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Barranquilla, 080020, Colombia
  • Research Site
    Medellín, 050010, Colombia
  • Research Site
    Medellín, 050025, Colombia
  • Research Site
    Aurillac, 15002, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Paris, 75013, France
  • Research Site
    Paris, 75018, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Kirchheim, 73230, Germany
  • Research Site
    Mainz Am Rhein, 55131, Germany
  • Research Site
    Budapest, 1085, Hungary
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Ahmedabad, 380005, India
  • Research Site
    Ahmedabad, 382421, India
  • Research Site
    Dehradun, 248001, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Hyderabad, 500082, India
  • Research Site
    Kolkata, 700020, India
  • Research Site
    Nadiād, 387001, India
  • Research Site
    Pune, 411001, India
  • Research Site
    Secunderabad, 500003, India
  • Research Site
    Vijayawada, 522002, India
  • Research Site
    Visakapatnam, 530013, India
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Cona, 44124, Italy
  • Research Site
    Eboli, 84025, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Bunkyō City, 113-8655, Japan
  • Research Site
    Chiba, 260-8712, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kita-gun, 761-0793, Japan
  • Research Site
    Kitakyushu-shi, 807-8555, Japan

Showing the first 100 of 164 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Almquist J, Chia YL, Tummala R, Bertagnolli L, Jayne D, Tang W, Lindholm C. Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. Clin Pharmacol Ther. 2026 Aug;120(2):429-439. doi: 10.1002/cpt.70307. Epub 2026 May 22. PubMed 42175562 ↗
  • Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230. PubMed 37528520 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean that all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Nov 30, 2021
StartActual
Feb 15, 2022
Primary completionEst.
Feb 23, 2027
CompletionEst.
Oct 4, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05138133
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 30, 2021
Start date
Feb 15, 2022
Primary completion
Feb 23, 2027 (estimated)
Completion
Oct 4, 2028 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion